XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity - RSUs and Revest Shares (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
cofounder
shares
Dec. 31, 2021
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense   $ 34,978,000 $ 33,426,000 $ 75,000,000 $ 64,264,000    
Modification expense, incremental fair value     1,200,000   1,200,000    
Signal Sciences Corp.              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of cofounders with shares subject to revesting | cofounder           3  
Shares held back for restricted stock awards, revesting period           2 years  
Signal Sciences Corp. | Common Stock—Class A              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares restricted for stock awards (in shares) | shares           896,499  
RSUs              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award vesting period       4 years      
Stock-based compensation expense   23,300,000 15,800,000 $ 45,100,000 29,000,000    
RSUs | First Year              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award vesting period       4 years      
Award vesting percentage       25.00%      
RSUs | Remaining Period              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award vesting period       36 months      
Revest Shares              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense   7,400,000 $ 11,000,000 $ 14,700,000 $ 21,900,000    
Nonvested shares sold that remain unvested (in shares) | shares             224,124
Proceeds from nonvested shares sold $ 10,700,000            
Modification expense, incremental fair value   $ 0   $ 5,600,000